No Clinical Benefit Suggested by Addition of Pulmozyme to Treatment of Critically Ill Patients With COVID-19 in I-SPY COVID Trial
SAN FRANCISCO, Jan. 10, 2022. Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the Pulmozyme (dornase alfa) arm of the trial has been terminated. The interim analysis suggests that the addition of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2022 Category: Pharmaceuticals Source Type: clinical trials
Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management
Condition: Loculated Empyema Intervention: Drug: Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg Sponsor: National University of Malaysia Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2021 Category: Research Source Type: clinical trials
Efficacy of Pulmozyme ® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)
Condition: Ischemic Stroke Intervention: Drug: Administration of dornase alfa Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2021 Category: Research Source Type: clinical trials
